BD and Tyrian ended their partnership to develop a point-of-care diagnostic for active tuberculosis because of an inability to consistently detect Tyrian's lead protein biomarker in clinical samples at high enough sensitivity and specificity levels.
The company will analyze protein targets of interest using shotgun mutagenesis mapping technology to identify amino acids essential for antibody binding and to discover and characterize cancer-specific biomarkers.
